Kalvista Pharmaceuticals (NASDAQ:KALV) released its quarterly earnings data on Monday. The specialty pharmaceutical company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.20, Fidelity Earnings reports. The business had revenue of $3.37 million for the quarter, compared to the consensus estimate of $3.24 million. Kalvista Pharmaceuticals had a negative net margin of 144.64% and a negative return on equity of 22.25%.
Shares of NASDAQ KALV opened at $16.00 on Thursday. The company’s fifty day moving average price is $16.01 and its 200 day moving average price is $21.37. Kalvista Pharmaceuticals has a 1 year low of $14.50 and a 1 year high of $34.92. The company has a market capitalization of $292.78 million, a PE ratio of -11.59 and a beta of 2.11.
KALV has been the topic of several recent research reports. Leerink Swann initiated coverage on shares of Kalvista Pharmaceuticals in a report on Monday, July 29th. They issued an “outperform” rating and a $31.00 price objective on the stock. Roth Capital set a $30.00 price objective on shares of Kalvista Pharmaceuticals and gave the company a “buy” rating in a report on Friday, September 6th. BidaskClub downgraded shares of Kalvista Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 6th. ValuEngine downgraded shares of Kalvista Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 2nd. Finally, Zacks Investment Research downgraded shares of Kalvista Pharmaceuticals from a “buy” rating to a “sell” rating in a report on Wednesday, July 17th. Two analysts have rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company’s stock. Kalvista Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $29.86.
In related news, insider Edward P. Feener sold 3,300 shares of the stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $18.62, for a total transaction of $61,446.00. Following the sale, the insider now directly owns 98,634 shares of the company’s stock, valued at $1,836,565.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Albert Cha purchased 61,280 shares of the stock in a transaction that occurred on Friday, July 19th. The shares were purchased at an average cost of $17.79 per share, for a total transaction of $1,090,171.20. The disclosure for this purchase can be found here. Insiders have purchased 145,427 shares of company stock worth $2,515,550 over the last three months. 21.60% of the stock is currently owned by insiders.
Kalvista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.